ATC Group: G02AD04 Carboprost

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G02AD04 in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G02 Other gynecologicals
3 G02A Oxytocics
4 G02AD Prostaglandins
5 G02AD04 Carboprost

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 2.5 mg

Active ingredients in G02AD04

Active Ingredient Description
Carboprost

Carboprost is a synthetic 15-methyl analogue of dinoprost (prostaglandin F2 alpha). Administered intramuscularly carboprost stimulates in the gravid uterus myometrial contractions similar to labor contractions at the end of a full term pregnancy. It is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and for the treatment of postpartum hemorrhage due to uterine atony, which has not responded to conventional methods of management. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle: vomiting, diarrhea, nausea, fever and flushing. Carboprost may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended.

Related product monographs

Title Information Source Document Type  
HEMABATE Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Canada (CA)

Hong Kong (HK)

New Zealand (NZ)

Singapore (SG)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.